CytomX Therapeutics
CTMX
103 hedge funds and large institutions have $438M invested in CytomX Therapeutics in 2025 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 12 closing their positions.
570% more call options, than puts
Call options by funds: $6.83M | Put options by funds: $1.02M
167% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 12
45% more capital invested
Capital invested by funds: $303M → $438M (+$136M)
24% more funds holding
Funds holding: 83 → 103 (+20)
16% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 25
82.02% less ownership
Funds ownership: 165.35% → 83.33% (-82%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.9M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$7.6M |
| 3 |
PA
Perceptive Advisors
New York
|
+$6.05M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.86M |
| 5 |
VA
VR Adviser
New York
|
+$3.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$13.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.04M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$8.85M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$6.65M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$6.5M |
CTMX Hedge Fund Activity: Q3 2025 in Review
103 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2025, worth a combined $438M — up 45% from $303M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new CTMX positions and 12 closed out — a net gain of 20 holders — while 29 added to existing stakes and 25 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $13.9M. The largest seller was Franklin Resources, exiting entirely with an estimated $13.1M sold.
- 103 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2025, up from 83 in Q2 2025.
- Funds reported $438M of CytomX Therapeutics stock for Q3 2025, up 45% quarter-over-quarter.
- 32 funds opened new CytomX Therapeutics positions in Q3 2025 and 12 closed out, a net change of +20 holders.
- The largest CytomX Therapeutics buyer in Q3 2025 was Fidelity Investments, an estimated $13.9M added.
- The largest CytomX Therapeutics seller in Q3 2025 was Franklin Resources, an estimated $13.1M sold.
Based on aggregated 13F filings for Q3 2025.